{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T03:11:52Z","timestamp":1785726712824,"version":"3.56.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40122-026-00816-z","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T17:25:43Z","timestamp":1770917143000},"page":"535-553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Retrospective Safety Analysis of OnabotulinumtoxinA for the Treatment of Patients with Chronic Migraine and Concomitant Therapeutic Indications"],"prefix":"10.1007","volume":"15","author":[{"given":"Andrew M.","family":"Blumenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Rhyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2765-7953","authenticated-orcid":false,"given":"Atul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5303-7992","authenticated-orcid":false,"given":"Kim","family":"Becker Ifantides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Yushmanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7052-9243","authenticated-orcid":false,"given":"Simona","family":"Battucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6588-751X","authenticated-orcid":false,"given":"Marc","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Forde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"816_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01402-2","volume":"23","author":"LJ Stovner","year":"2022","unstructured":"Stovner LJ, Hagen K, Linde M, Steiner TJ. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022;23:34.","journal-title":"J Headache Pain"},{"key":"816_CR2","first-page":"1","volume":"38","author":"Headache Classification Committee of the International Headache Society","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211.","journal-title":"Cephalalgia"},{"key":"816_CR3","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1111\/head.13421","volume":"58","author":"SD Silberstein","year":"2018","unstructured":"Silberstein SD, Lee L, Gandhi K, Fitzgerald T, Bell J, Cohen JM. Health care resource utilization and migraine disability along the migraine continuum among patients treated for migraine. Headache. 2018;58:1579\u201392.","journal-title":"Headache"},{"key":"816_CR4","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1111\/j.1526-4610.2012.02223.x","volume":"52","author":"DC Buse","year":"2012","unstructured":"Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention study. Headache. 2012;52:1456\u201370.","journal-title":"Headache"},{"key":"816_CR5","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1046\/j.1526-4610.2003.03068.x","volume":"43","author":"ME Bigal","year":"2003","unstructured":"Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache. 2003;43:336\u201342.","journal-title":"Headache"},{"key":"816_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","volume":"81","author":"DC Buse","year":"2010","unstructured":"Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81:428\u201332.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"816_CR7","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1111\/head.13966","volume":"60","author":"DC Buse","year":"2020","unstructured":"Buse DC, Reed ML, Fanning KM, Bostic RC, Lipton RB. Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: results of the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2020;60:2340\u201356.","journal-title":"Headache"},{"key":"816_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2021.640574","volume":"15","author":"C Altamura","year":"2021","unstructured":"Altamura C, Corbelli I, de Tommaso M, et al. Pathophysiological bases of comorbidity in migraine. Front Hum Neurosci. 2021;15:640574.","journal-title":"Front Hum Neurosci"},{"issue":"Suppl 1","key":"816_CR9","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1007\/s10072-012-1042-9","volume":"33","author":"F d'Onofrio","year":"2012","unstructured":"d\u2019Onofrio F, Barbanti P, Petretta V, et al. Migraine and movement disorders. Neurol Sci. 2012;33(Suppl 1):S55\u20139.","journal-title":"Neurol Sci"},{"key":"816_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1177\/0333102417690127","volume":"38","author":"ML Ramos","year":"2018","unstructured":"Ramos ML, Garc\u00eda-Cabo C, Leira R, et al. Comorbidity between idiopathic overactive bladder and chronic migraine. Cephalalgia. 2018;38:581\u20134.","journal-title":"Cephalalgia"},{"key":"816_CR11","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/head.14753","volume":"64","author":"M Matharu","year":"2024","unstructured":"Matharu M, Katsarava Z, Buse DC, et al. Characterizing neck pain during headache among people with migraine: multicountry results from the Chronic Migraine Epidemiology and Outcomes\u2014International (CaMEO-I) cross-sectional study. Headache. 2024;64:750\u201363.","journal-title":"Headache"},{"key":"816_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11916-012-0268-9","volume":"16","author":"DA Gon\u00e7alves","year":"2012","unstructured":"Gon\u00e7alves DA, Camparis CM, Franco AL, Fernandes G, Speciali JG, Bigal ME. How to investigate and treat: migraine in patients with temporomandibular disorders. Curr Pain Headache Rep. 2012;16:359\u201364.","journal-title":"Curr Pain Headache Rep"},{"key":"816_CR13","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1212\/WNL.0b013e3182752c5a","volume":"79","author":"AR Gardiner","year":"2012","unstructured":"Gardiner AR, Bhatia KP, Stamelou M, et al. PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine. Neurology. 2012;79:2115\u201321.","journal-title":"Neurology"},{"key":"816_CR14","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/j.1469-8749.2012.04394.x","volume":"54","author":"RC Dale","year":"2012","unstructured":"Dale RC, Gardiner A, Antony J, Houlden H. Familial PRRT2 mutation with heterogeneous paroxysmal disorders including paroxysmal torticollis and hemiplegic migraine. Dev Med Child Neurol. 2012;54:958\u201360.","journal-title":"Dev Med Child Neurol"},{"key":"816_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.5213\/inj.2040186.093","volume":"24","author":"A Baser","year":"2020","unstructured":"Baser A, Elia\u00e7\u0131k S, Baykam MM, Tan FU. Clinical manifestations of overactive bladder with migraine as a comorbidity: a prospective cross-sectional study. Int Neurourol J. 2020;24:375\u201381.","journal-title":"Int Neurourol J"},{"key":"816_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.juro.2016.02.076","volume":"196","author":"D Altman","year":"2016","unstructured":"Altman D, Iliadou AN, Lundholm C, Milsom I, Pedersen NL. Somatic comorbidity in women with overactive bladder syndrome. J Urol. 2016;196:473\u20137.","journal-title":"J Urol"},{"key":"816_CR17","unstructured":"Botox [package insert]. North Chicago, IL: AbbVie; 2023."},{"key":"816_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032373","volume":"102","author":"MF Brin","year":"2023","unstructured":"Brin MF, Blitzer A. The pluripotential evolution and journey of Botox (onabotulinumtoxinA). Medicine (Baltimore). 2023;102:e32373.","journal-title":"Medicine (Baltimore)"},{"key":"816_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0840-8","volume":"19","author":"AM Blumenfeld","year":"2018","unstructured":"Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A. Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19:13.","journal-title":"J Headache Pain"},{"key":"816_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0976-1","volume":"20","author":"F Ahmed","year":"2019","unstructured":"Ahmed F, Gaul C, Garcia-Monco JC, Sommer K, Martelletti P. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. J Headache Pain. 2019;20:26.","journal-title":"J Headache Pain"},{"key":"816_CR21","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","volume":"51","author":"SK Aurora","year":"2011","unstructured":"Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51:1358\u201373.","journal-title":"Headache"},{"key":"816_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-15-54","volume":"15","author":"M Khalil","year":"2014","unstructured":"Khalil M, Zafar HW, Quarshie V, Ahmed F. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK. J Headache Pain. 2014;15:54.","journal-title":"J Headache Pain"},{"key":"816_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01721-6","volume":"25","author":"L Grazzi","year":"2024","unstructured":"Grazzi L, Giossi R, Montisano DA, et al. Real-world effectiveness of anti-CGRP monoclonal antibodies compared to onabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study. J Headache Pain. 2024;25:14.","journal-title":"J Headache Pain"},{"key":"816_CR24","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/ene.13657","volume":"25","author":"AP Andreou","year":"2018","unstructured":"Andreou AP, Trimboli M, Al-Kaisy A, Murphy M, Palmisani S, Fenech C, et al. Prospective real-world analysis of onabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal. Eur J Neurol. 2018;25:1069-e83.","journal-title":"Eur J Neurol"},{"key":"816_CR25","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/j.1526-4610.2012.02164.x","volume":"52","author":"PK Winner","year":"2012","unstructured":"Winner PK, Sadowsky CH, Martinez WC, Zuniga JA, Poulette A. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine. Headache. 2012;52:1219\u201325.","journal-title":"Headache"},{"key":"816_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2165\/00126839-200809030-00002","volume":"9","author":"AJ Dowson","year":"2008","unstructured":"Dowson AJ, Kilminster SG, Salt R. Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: a prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting. Drugs R D. 2008;9:147\u201358.","journal-title":"Drugs R D"},{"key":"816_CR27","first-page":"330","volume":"55","author":"G Kocaman","year":"2018","unstructured":"Kocaman G, Kahraman N, K\u00f6seo\u011flu BG, et al. Evaluation of onabotulinumtoxinA treatment in patients with concomitant chronic migraine and temporomandibular disorders. Noro Psikiyatr Ars. 2018;55:330\u20136.","journal-title":"Noro Psikiyatr Ars"},{"key":"816_CR28","unstructured":"Rodriguez R, Broner SW, Forde G, et al, editors. Real-world diagnosis of chronic migraine in patients with cervical dystonia analyzed by botulinum neurotoxin treatment exposure: an epidemiologic perspective. Annual Meeting of the International Congress of Parkinson's Disease and Movement Disorders; September 27\u2013October 1, 2024; Philadelphia, PA."},{"key":"816_CR29","unstructured":"Sarva H, Hillson E, Sadeghi M, Pinsky B, Broner S, editors. Annual real-world diagnosis and health care costs among patients with comorbid cervical dystonia and chronic migraine. Annual Assembly of the American Academy of Physical Medicine and Rehabilitation; November 6\u201310, 2024; San Diego, CA."},{"key":"816_CR30","doi-asserted-by":"publisher","unstructured":"Chiu SY, Patel B, Burns MR, et al. High-dose botulinum toxin therapy: safety, benefit, and endurance of efficacy. Tremor Other Hyperkinet Mov (N Y). 2020;10. https:\/\/doi.org\/10.7916\/tohm.v0.749.","DOI":"10.7916\/tohm.v0.749"},{"key":"816_CR31","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.urology.2014.07.046","volume":"84","author":"U Nuanthaisong","year":"2014","unstructured":"Nuanthaisong U, Abraham N, Goldman HB. Incidence of adverse events after high doses of onabotulinumtoxinA for multiple indications. Urology. 2014;84:1044\u20138.","journal-title":"Urology"},{"key":"816_CR32","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","volume":"37","author":"RC Burch","year":"2019","unstructured":"Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37:631\u201349.","journal-title":"Neurol Clin"},{"key":"816_CR33","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/toxins16100420","volume":"16","author":"G Forde","year":"2024","unstructured":"Forde G, Brucker BM, Becker Ifantides K, et al. SYNCHRONIZE: real-world retrospective safety analysis of patients treated with onabotulinumtoxinA for more than one therapeutic indication. Toxins (Basel). 2024;16:420.","journal-title":"Toxins (Basel)"},{"key":"816_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/toxins11090491","author":"S Bellows","year":"2019","unstructured":"Bellows S, Jankovic J. Immunogenicity associated with botulinum toxin treatment. Toxins (Basel). 2019. https:\/\/doi.org\/10.3390\/toxins11090491.","journal-title":"Toxins (Basel)"},{"key":"816_CR35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jns.2014.12.030","volume":"349","author":"J Jankovic","year":"2015","unstructured":"Jankovic J, Adler CH, Charles D, et al. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci. 2015;349:84\u201393.","journal-title":"J Neurol Sci"},{"key":"816_CR36","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/papr.12408","volume":"16","author":"PD Charles","year":"2016","unstructured":"Charles PD, Manack Adams A, Davis T, et al. Neck pain and cervical dystonia: treatment outcomes from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). Pain Pract. 2016;16:1073\u201382.","journal-title":"Pain Pract"},{"key":"816_CR37","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00415-014-7343-6","volume":"261","author":"PD Charles","year":"2014","unstructured":"Charles PD, Adler CH, Stacy M, et al. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol. 2014;261:1309\u201319.","journal-title":"J Neurol"},{"key":"816_CR38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/head.14467","volume":"63","author":"A Zolin","year":"2023","unstructured":"Zolin A, Broner SW, Yoo A, et al. Dystonia phenomenology and treatment response in migraine. Headache. 2023;63:255\u201363.","journal-title":"Headache"},{"key":"816_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/toxins15050342","author":"J Jankovic","year":"2023","unstructured":"Jankovic J, Carruthers J, Naumann M, et al. Neutralizing antibody formation with onabotulinumtoxinA (BOTOX(\u00ae)) treatment from global registration studies across multiple indications: a meta-analysis. Toxins (Basel). 2023. https:\/\/doi.org\/10.3390\/toxins15050342.","journal-title":"Toxins (Basel)"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-026-00816-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-026-00816-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-026-00816-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:15:11Z","timestamp":1774419311000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-026-00816-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["816"],"URL":"https:\/\/doi.org\/10.1007\/s40122-026-00816-z","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrew M. Blumenfeld has served on advisory boards for, consulted for, and\/or been a speaker or contributing author for AbbVie, Aeon, Alder, Allergan, Amgen, Axon, Axsome, Bausch Health, Biohaven, Equinox, Ipsen, Lilly, Lundbeck, Novartis, Pfizer, Revance, Teva, Theranica, and Zosano. He has received grant support from AbbVie, Amgen, and Lundbeck. He owns stock options for Aeon, Axon, and Haven. He is an Editorial Board member of\n                      Pain and Therapy\n                      ; he was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Christopher Rhyne has no conflicts to disclose. Kenneth Martinez has received personal compensation for serving as a consultant for Merz and Revance. The institution of KM has received compensation for him serving as a consultant for Abbott, AbbVie, Amgen\/Novartis, and Biohaven and on a speakers bureau for AbbVie and Merz. The institution of Kenneth Martinez has received research support from AbbVie, Boston Scientific, and Medtronic. Atul Patel is a consultant for AbbVie, Ipsen, and Revance; a speaker for AbbVie and Ipsen; and has received research grant support from AbbVie and Ipsen. Kim Becker Ifantides, Ritu Singh, Irina Yushmanova, and Simona Battucci are employees of AbbVie and may hold AbbVie stock. Marc Schwartz has served as a biostatistical consultant for Allergan, an AbbVie company. Grace Forde has received compensation from AbbVie for serving as a speaker.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The SYNCHRONIZE study was conducted in accordance with the ethical principles set forth in the Declaration of Helsinki principles consistent with good clinical practice and all applicable regulatory requirements. Informed consent was not required because no identifiable patient information was obtained. All study-related documents were approved by independent ethics committees and IRBs at each of the following sites in the USA: EvergreenHealth Multiple Sclerosis Center Kirkland, Kirkland, WA (approved June 21, 2021); Lucetta, LLC\/Grace Forde, Lake Success, NY (approved January 26, 2022); Swedish Neuroscience Institute MS Center, Seattle, WA (approved April 19, 2022); Kansas Institute of Research, Overland Park, KS (approved January 23, 2022); Neuroscience Group, Neenah, WI (approved February 3, 2022); Neurology and Pain Specialty Center, Aliso Viejo, CA (approved January 27, 2022); Diamond Headache Clinic Chicago, IL (approved January 21, 2022); Rush University Medical Center, Chicago, IL (approved January 1, 2022); NYU Langone Health, New York, NY (approved February 19, 2022); and Rancho Research Institute, Rancho Los Amigos National Rehabilitation Center, Downey, CA (approved February 27, 2022).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}